# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $5 p...
It expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $13...
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate o...
Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $5 p...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $5 p...